Steve Lincoln serves as Interim General Counsel, Chief Compliance Officer for Scilex Holding Company and Scilex Pharmaceuticals. Steve has been involved in the biopharma industry for more than 18 years. Most recently, he has been Of Counsel to the law firm of Brown Gee & Wenger, where his corporate practice has included several publicly traded and private biopharma companies. Before that, Steve served in in-house counsel roles at SciClone Pharmaceuticals (acquired by GL Capital), Kosan Biosciences (acquired by Bristol Myers Squibb), SuperGen (now Astex Pharmaceuticals, a subsidiary of Otsuka), and Protein Design Labs (later Facet Biotech, acquired by AbbVie). Steve is a graduate of Brown University and the Boston University School of Law.